SE0200198D0 - New use - Google Patents

New use

Info

Publication number
SE0200198D0
SE0200198D0 SE0200198A SE0200198A SE0200198D0 SE 0200198 D0 SE0200198 D0 SE 0200198D0 SE 0200198 A SE0200198 A SE 0200198A SE 0200198 A SE0200198 A SE 0200198A SE 0200198 D0 SE0200198 D0 SE 0200198D0
Authority
SE
Sweden
Prior art keywords
new use
melagatran
diabetes
medicament
pharmaceutically
Prior art date
Application number
SE0200198A
Other languages
English (en)
Swedish (sv)
Inventor
Olle Korsgren
Bo Nilsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0200198A priority Critical patent/SE0200198D0/xx
Publication of SE0200198D0 publication Critical patent/SE0200198D0/xx
Priority to JP2003561625A priority patent/JP2005516035A/ja
Priority to NZ533749A priority patent/NZ533749A/en
Priority to US10/502,069 priority patent/US7045502B2/en
Priority to IL16285303A priority patent/IL162853A0/xx
Priority to CA002472241A priority patent/CA2472241A1/en
Priority to CNB038026740A priority patent/CN100430089C/zh
Priority to BR0306798-0A priority patent/BR0306798A/pt
Priority to MXPA04007192A priority patent/MXPA04007192A/es
Priority to KR10-2004-7011228A priority patent/KR20040075096A/ko
Priority to EP03701203A priority patent/EP1469874A1/en
Priority to PCT/SE2003/000087 priority patent/WO2003061682A1/en
Priority to ZA2004/05342A priority patent/ZA200405342B/en
Priority to NO20043483A priority patent/NO20043483L/no
Priority to US11/362,890 priority patent/US20060148720A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0200198A 2002-01-23 2002-01-23 New use SE0200198D0 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use
PCT/SE2003/000087 WO2003061682A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
CNB038026740A CN100430089C (zh) 2002-01-23 2003-01-21 美拉加群在制造治疗i型糖尿病的药物中的用途
MXPA04007192A MXPA04007192A (es) 2002-01-23 2003-01-21 Uso de melagatrana para la manufactura de un medicamento para el tratamiento de diabetes mellitus tipo i.
US10/502,069 US7045502B2 (en) 2002-01-23 2003-01-21 Use of melagatran for the manufacture of a medicament for the treatment of Type 1 diabetes mellitus
IL16285303A IL162853A0 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
CA002472241A CA2472241A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
JP2003561625A JP2005516035A (ja) 2002-01-23 2003-01-21 Ｉ型糖尿病の処置に用いる医薬の製造のための、メラガトランの使用
BR0306798-0A BR0306798A (pt) 2002-01-23 2003-01-21 Uso de melagatran ou de um derivado farmaceuticamente aceitável deste, métodos de tratamento de diabetes mellitus tipo i, de transplante de células de enxertamento de ilhotas de langerhans, para melhorar a independência de insulina em pacientes com diabetes mellitus tipo i, e de tratamento de reação inflamatória mediada pelo sangue instantânea, formulação farmacêutica para uso no tratamento de diabetes mellitus tipo i, kit de partes, e, método de fabricação de um kit de partes.
NZ533749A NZ533749A (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
KR10-2004-7011228A KR20040075096A (ko) 2002-01-23 2003-01-21 유형ｉ 당뇨를 치료하기 위한 약제 제조용 멜라가트란의용도
EP03701203A EP1469874A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
ZA2004/05342A ZA200405342B (en) 2002-01-23 2004-07-05 The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus
NO20043483A NO20043483L (no) 2002-01-23 2004-08-20 Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus
US11/362,890 US20060148720A1 (en) 2002-01-23 2006-02-24 Use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use

Publications (1)

Publication Number Publication Date
SE0200198D0 true SE0200198D0 (sv) 2002-01-23

Family

ID=20286751

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use

Country Status (14)

Country Link
US (2) US7045502B2 (enExample)
EP (1) EP1469874A1 (enExample)
JP (1) JP2005516035A (enExample)
KR (1) KR20040075096A (enExample)
CN (1) CN100430089C (enExample)
BR (1) BR0306798A (enExample)
CA (1) CA2472241A1 (enExample)
IL (1) IL162853A0 (enExample)
MX (1) MXPA04007192A (enExample)
NO (1) NO20043483L (enExample)
NZ (1) NZ533749A (enExample)
SE (1) SE0200198D0 (enExample)
WO (1) WO2003061682A1 (enExample)
ZA (1) ZA200405342B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
RU2017144535A (ru) 2010-03-30 2019-02-18 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
BR112015023214A8 (pt) 2013-03-15 2019-12-24 Verseon Corp composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
PL2968297T3 (pl) 2013-03-15 2019-04-30 Verseon Corp Wielopodstawione związki aromatyczne jako inhibitory protezy serynowej
EP3194369A4 (en) 2014-09-17 2018-02-28 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CA2977993A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
WO2020014669A1 (en) 2018-07-13 2020-01-16 Verseon Corporation Thrombin inhibitors, formulations, and uses thereof
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
CA3244101A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. MODIFIED CD47 PROTEINS AND THEIR USES
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use

Also Published As

Publication number Publication date
US20050090424A1 (en) 2005-04-28
KR20040075096A (ko) 2004-08-26
IL162853A0 (en) 2005-11-20
WO2003061682A1 (en) 2003-07-31
US20060148720A1 (en) 2006-07-06
NO20043483L (no) 2004-08-20
CA2472241A1 (en) 2003-07-31
NZ533749A (en) 2006-02-24
ZA200405342B (en) 2005-09-28
US7045502B2 (en) 2006-05-16
CN1729010A (zh) 2006-02-01
BR0306798A (pt) 2004-12-07
EP1469874A1 (en) 2004-10-27
CN100430089C (zh) 2008-11-05
JP2005516035A (ja) 2005-06-02
MXPA04007192A (es) 2004-10-29

Similar Documents

Publication Publication Date Title
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE408601T1 (de) Fredericamycin-derivate
EA200600223A1 (ru) Замещённый 2-аминотетралины для лечения депрессии
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
DK1558579T3 (da) N-alkyl-4-methylenamino-3-hydroxy-2-pyridoner som antimikrobialer
JO2282B1 (en) Oxazole derivatives
DK1694318T3 (da) (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
EA200800302A1 (ru) Применение производных и аналогов тиазола при лечении рака
SE0200198D0 (sv) New use
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
DE60128100D1 (de) Analgetisches arzneimittel
DK1558580T3 (da) N-sulfonyl-4-methylenamino-3-hydroxy-2-pyridoner
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
SE0002739D0 (sv) New use
DE602005011267D1 (de) Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
NO20033413L (no) Krystallmodifisering av et syklisk depsipeptid med forbedret aktivitet
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
SE0300535D0 (sv) Treatment of burns